Effects of supplementation with curcumin on serum adipokine concentrations: A randomized controlled trial

Nutrition

Volumn 32, Issue 10, 2016, Pages 1116-1122

  Panahi, Yunes ^a   Hosseini, Mahboobeh Sadat ^a   Khalili, Nahid ^a   Naimi, Effat ^a   Soflaei, Sara Saffar ^b   Majeed, Muhammed ^c   Sahebkar, Amirhossein ^d,e  

^a BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c Sabinsa Inc   (United States)

^d MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Adiponectin; Curcumin; Leptin; Meta analysis; Metabolic syndrome

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; CURCUMIN; GLUCOSE; HEMOGLOBIN A1C; LEPTIN; LIPID; PIPERINE; PLACEBO; ADIPOQ PROTEIN, HUMAN; GLUCOSE BLOOD LEVEL;

ADIPONECTIN LEPTIN RATIO; ADULT; ANALYTICAL PARAMETERS; ARTICLE; BODY MASS; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DOWN REGULATION; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG RESPONSE; DRUG TOLERABILITY; EVIDENCE BASED PRACTICE; FEMALE; GLUCOSE BLOOD LEVEL; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; METABOLIC SYNDROME X; PARALLEL DESIGN; PILOT STUDY; POST HOC ANALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SUPPLEMENTATION; TREATMENT DURATION; UPREGULATION; BLOOD; DIET THERAPY; DIETARY SUPPLEMENT; INSULIN RESISTANCE; METABOLISM; MIDDLE AGED;

ADIPOKINES; ADIPONECTIN; ADULT; BLOOD GLUCOSE; CURCUMIN; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INSULIN RESISTANCE; LEPTIN; LIPIDS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PILOT PROJECTS;

EID: 84991093502     PISSN: 08999007     EISSN: 18731244     Source Type: Journal    
DOI: 10.1016/j.nut.2016.03.018     Document Type: Article

References (65)

1. [1] Reaven, G.M., Role of insulin resistance in human disease. Diabetes 37 (1988), 1595–1607.
2. [2] Grundy, S.M., Metabolic syndrome update. Trends Cardiovasc Med 26 (2016), 364–373.
3. [3] Azimi-Nezhad, M., Herbeth, B., Siest, G., Dadé, S., Ndiaye, N.C., Esmaily, H., et al. High prevalence of metabolic syndrome in Iran in comparison with France: what are the components that explain this?. Metab Syndr Relat Disord 10 (2012), 181–188.
4. [4] Liu, M., Liu, F., Transcriptional and post-translational regulation of adiponectin. Biochem J 425 (2010), 41–52.
5. [5] Matsuzawa, Y., Funahashi, T., Kihara, S., Shimomura, I., Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 24 (2004), 29–33.
6. [6] Xydakis, A.M., Case, C.C., Jones, P.H., Hoogeveen, R.C., Liu, M.Y., Smith, E.O., et al. Adiponectin, inflammation, and the expression of the metabolic syndrome in obese individuals: the impact of rapid weight loss through caloric restriction. J Clin Endocrinol Metab 89 (2004), 2697–2703.
7. [7] Lee, H., Lee, M., Joung, H., Adiponectin represents an independent risk factor for hypertension in middle aged Korean women. Asia Pac J Clin Nutr, 16, 2007, 10.
8. [8] Lau, D.C., Dhillon, B., Yan, H., Szmitko, P.E., Verma, S., Adipokines: molecular links between obesity and atheroslcerosis. Am J Physiol Heart Circ Physiol 288 (2005), H2031–H2041.
9. [9] Hutley, L., Prins, J.B., Fat as an endocrine organ: relationship to the metabolic syndrome. Am J Med Sci 330 (2005), 280–289.
10. [10] Wallace, A.M., McMahon, A.D., Packard, C.J., Kelly, A., Shepherd, J., Gaw, A., et al. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation 104 (2001), 3052–3056.
11. [11] Considine, R.V., Sinha, M.K., Heiman, M.L., Kriauciunas, A., Stephens, T.W., Nyce, M.R., et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 334 (1996), 292–295.
12. [12] Panahi, Y., Badeli, R., Karami, G.R., Sahebkar, A., Investigation of the efficacy of adjunctive therapy with bioavailability-boosted curcuminoids in major depressive disorder. Phytother Res 29 (2015), 17–21.
13. [13] Esmaily, H., Sahebkar, A., Iranshahi, M., Ganjali, S., Mohammadi, A., Ferns, G., et al. An investigation of the effects of curcumin on anxiety and depression in obese individuals: a randomized controlled trial. Chin J Integr Med 21 (2015), 332–338.
14. [14] Panahi, Y., Alishiri, G.H., Parvin, S., Sahebkar, A., Mitigation of systemic oxidative stress by curcuminoids in osteoarthritis: results of a randomized controlled trial. J Diet Suppl 13 (2016), 209–220.
15. [15] Panahi, Y., Rahimnia, A.R., Sharafi, M., Alishiri, G., Saburi, A., Sahebkar, A., Curcuminoid treatment for knee osteoarthritis: a randomized double-blind placebo-controlled trial. Phytother Res 28 (2014), 1625–1631.
16. [16] Panahi, Y., Hosseini, M.S., Khalili, N., Naimi, E., Majeed, M., Sahebkar, A., Antioxidant and anti-inflammatory effects of curcuminoid-piperine combination in subjects with metabolic syndrome: a randomized controlled trial and an updated meta-analysis. Clin Nutr 34 (2015), 1101–1108.
17. [17] Panahi, Y., Khalili, N., Hosseini, M.S., Abbasinazari, M., Sahebkar, A., Lipid-modifying effects of adjunctive therapy with curcuminoids–piperine combination in patients with metabolic syndrome: results of a randomized controlled trial. Complement Ther Med 22 (2014), 851–857.
18. [18] Sahebkar, A., Curcuminoids for the management of hypertriglyceridaemia. Nat Rev Cardiol, 11, 2014, 123.
19. [19] Mohammadi, A., Sahebkar, A., Iranshahi, M., Amini, M., Khojasteh, R., Ghayour-Mobarhan, M., et al. Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial. Phytother Res 27 (2013), 374–379.
20. [20] Sahebkar, A., Dual effect of curcumin in preventing atherosclerosis: the potential role of pro-oxidant–antioxidant mechanisms. Nat Prod Res 29 (2015), 1–2.
21. [21] Sahebkar, A., Molecular mechanisms for curcumin benefits against ischemic injury. Fertil Steril 94 (2010), e75–e76.
22. [22] Panahi, Y., Ghanei, M., Bashiri, S., Hajihashemi, A., Sahebkar, A., Short-term curcuminoid supplementation for chronic pulmonary complications due to sulfur mustard intoxication: positive results of a randomized double-blind placebo-controlled trial. Drug Res 65 (2015), 567–573.
23. [23] Panahi, Y., Sahebkar, A., Parvin, S., Saadat, A., A randomized controlled trial on the anti-inflammatory effects of curcumin in patients with chronic sulphur mustard-induced cutaneous complications. Ann Clin Biochem 49 (2012), 580–588.
24. [24] Panahi, Y., Ghanei, M., Hajhashemi, A., Sahebkar, A., Effects of curcuminoids-piperine combination on systemic oxidative stress, clinical symptoms and quality of life in subjects with chronic pulmonary complications due to sulfur mustard: a randomized controlled trial. J Diet Suppl 13 (2016), 93–105.
25. [25] Panahi, Y., Sahebkar, A., Amiri, M., Davoudi, S.M., Beiraghdar, F., Hoseininejad, S.L., et al. Improvement of sulphur mustard-induced chronic pruritus, quality of life and antioxidant status by curcumin: results of a randomised, double-blind, placebo-controlled trial. Br J Nutr 108 (2012), 1272–1279.
26. [26] Panahi, Y., Saadat, A., Beiraghdar, F., Sahebkar, A., Adjuvant therapy with bioavailability-boosted curcuminoids suppresses systemic inflammation and improves quality of life in patients with solid tumors: a randomized double-blind placebo-controlled trial. Phytother Res 28 (2014), 1461–1467.
27. [27] Sahebkar, A., Are curcuminoids effective C-reactive protein-lowering agents in clinical practice? Evidence from a meta-analysis. Phytother Res 28 (2014), 633–642.
28. [28] Sahebkar, A., Mohammadi, A., Atabati, A., Rahiman, S., Tavallaie, S., Iranshahi, M., et al. Curcuminoids modulate pro-oxidant–antioxidant balance but not the immune response to heat shock protein 27 and oxidized LDL in obese individuals. Phytother Res 27 (2013), 1883–1888.
29. [29] Panahi, Y., Kianpour, P., Mohtashami, R., Jafari, R., Simental-Mendía, L.E., Sahebkar, A., A Curcumin lowers serum lipids and uric acid in subjects with non-alcoholic fatty liver disease: a randomized controlled trial. J Cardiovasc Pharmacol, 2016, 10.1097/FJC.0000000000000406.
30. [30] Sahebkar, A., Why it is necessary to translate curcumin into clinical practice for the prevention and treatment of metabolic syndrome?. Biofactors 39 (2013), 197–208.
31. [31] Ramırez-Boscá, A., Soler, A., Carrion, M.A., Dıaz-Alperi, J., Bernd, A., Quintanilla, C., et al. An hydroalcoholic extract of Curcuma longa lowers the apo B/apo A ratio: implications for atherogenesis prevention. Mech Ageing Dev 119 (2000), 41–47.
32. [32] Boscá, A.R., Soler, A., Carrión-Gutiérrez, M.A., Mira, D.P., Zapata, J.P., Diaz-Alperi, J., et al. An hydroalcoholic extract of Curcuma longa lowers the abnormally high values of human-plasma fibrinogen. Mech Ageing Dev 114 (2000), 207–210.
33. [33] Alwi, I., Santoso, T., Suyono, S., Sutrisna, B., Suyatna, F.D., Kresno, S.B., et al. The effect of curcumin on lipid level in patients with acute coronary syndrome. Acta Med Indones 40 (2008), 201–210.
34. [34] Baum, L., Cheung, S.K., Mok, V.C., Lam, L.C., Leung, V.P., Hui, E., et al. Curcumin effects on blood lipid profile in a 6-month human study. Pharmacol Res 56 (2007), 509–514.
35. [35] Soni, K., Kuttan, R., Effect of oral curcumin administration on serum peroxides and cholesterol levels in human volunteers. Indian J Physiol Pharmacol 36 (1992), 273–275.
36. [36] Seo, K.I., Choi, M.S., Jung, U.J., Kim, H.J., Yeo, J., Jeon, S.M., et al. Effect of curcumin supplementation on blood glucose, plasma insulin, and glucose homeostasis related enzyme activities in diabetic db/db mice. Mol Nutr Food Res 52 (2008), 995–1004.
37. [37] Pari, L., Murugan, P., Changes in glycoprotein components in streptozotocin-nicotinamide induced type 2 diabetes: influence of tetrahydrocurcumin from Curcuma longa. Plant Foods Hum Nutr 62 (2007), 25–29.
38. [38] Kuroda, M., Mimaki, Y., Nishiyama, T., Mae, T., Kishida, H., Tsukagawa, M., et al. Hypoglycemic effects of turmeric (Curcuma longa L. rhizomes) on genetically diabetic KK-Ay mice. Biol Pharm Bull 28 (2005), 937–939.
39. [39] Jang, E.M., Choi, M.S., Jung, U.J., Kim, M.J., Kim, H.J., Jeon, S.M., et al. Beneficial effects of curcumin on hyperlipidemia and insulin resistance in high-fat–fed hamsters. Metabolism 57 (2008), 1576–1583.
40. [40] Ejaz, A., Wu, D., Kwan, P., Meydani, M., Curcumin inhibits adipogenesis in 3 T3-L1 adipocytes and angiogenesis and obesity in C57/BL mice. J Nutr 139 (2009), 919–925.
41. [41] Shao, W., Yu, Z., Chiang, Y., Yang, Y., Chai, T., Foltz, W., et al. Curcumin prevents high fat diet induced insulin resistance and obesity via attenuating lipogenesis in liver and inflammatory pathway in adipocytes. PLoS One, 7, 2012, e28784.
42. [42] Weisberg, S.P., Leibel, R., Tortoriello, D.V., Dietary curcumin significantly improves obesity-associated inflammation and diabetes in mouse models of diabesity. Endocrinology 149 (2008), 3549–3558.
43. [43] Nakmareong, S., Kukongviriyapan, U., Pakdeechote, P., Donpunha, W., Kukongviriyapan, V., Kongyingyoes, B., et al. Antioxidant and vascular protective effects of curcumin and tetrahydrocurcumin in rats with L-NAME-induced hypertension. Naunyn Schmiedebergs Arch Pharmacol 383 (2011), 519–529.
44. [44] Shehzad, A., Ha, T., Subhan, F., Lee, Y.S., New mechanisms and the anti-inflammatory role of curcumin in obesity and obesity-related metabolic diseases. Eur J Nutr 50 (2011), 151–161.
45. [45] Kubota, M., Shimizu, M., Sakai, H., Yasuda, Y., Terakura, D., Baba, A., et al. Preventive effects of curcumin on the development of azoxymethane-induced colonic preneoplastic lesions in male C57 BL/KsJ-db/db obese mice. Nutr Cancer 64 (2012), 72–79.
46. [46] Cleeman, J., Grundy, S., Becker, D., Clark, L., Expert panel on detection, evaluation and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP III). JAMA 285 (2001), 2486–2497.
47. [47] Atal, C., Dubey, R., Singh, J., Biochemical basis of enhanced drug bioavailability by piperine: evidence that piperine is a potent inhibitor of drug metabolism. J Pharmacol Exp Ther 232 (1985), 258–262.
48. [48] Asgary, S., Sahebkar, A., Afshani, M.R., Keshvari, M., Haghjooyjavanmard, S., Rafieian-Kopaei, M., Clinical evaluation of blood pressure lowering, endothelial function improving, hypolipidemic and anti-inflammatory effects of pomegranate juice in hypertensive subjects. Phytother Res 28 (2014), 193–199.
49. [49] Borenstein, M., Hedges, L., Higgins, J., Rothstein, H., Comprehensive meta-analysis version 2. 2005, Biostat, Englewood, NJ, 104.
50. [50] Chuengsamarn, S., Rattanamongkolgul, S., Luechapudiporn, R., Phisalaphong, C., Jirawatnotai, S., Curcumin extract for prevention of type 2 diabetes. Diabetes Care 35 (2012), 2121–2127.
51. [51] Chuengsamarn, S., Rattanamongkolgul, S., Phonrat, B., Tungtrongchitr, R., Jirawatnotai, S., Reduction of atherogenic risk in patients with type 2 diabetes by curcuminoid extract: a randomized controlled trial. J Nutr Biochem 25 (2014), 144–150.
52. [52] Lopresti, A.L., Maes, M., Meddens, M.J., Maker, G.L., Arnoldussen, E., Drummond, P.D., Curcumin and major depression: a randomised, double-blind, placebo-controlled trial investigating the potential of peripheral biomarkers to predict treatment response and antidepressant mechanisms of change. Eur Neuropsychopharmacol 25 (2015), 38–50.
53. [53] Castro, A.V., Kolka, C.M., Kim, S.P., Bergman, R.N., Obesity, insulin resistance and comorbidities? Mechanisms of association. Arq Bras Endocrinol Metabol 58 (2014), 600–609.
54. [54] Shoelson, S.E., Lee, J., Goldfine, A.B., Inflammation and insulin resistance. J Clin Invest, 116, 2006, 1793.
55. [55] Vettor, R., Milan, G., Rossato, M., Federspil, G., Review article: adipocytokines and insulin resistance. Aliment Pharmacol Ther 22 (2005), 3–10.
56. [56] Finucane, F.M., Luan, J., Wareham, N.J., Sharp, S.J., O'Rahilly, S., Balkau, B., et al. Correlation of the leptin:adiponectin ratio with measures of insulin resistance in non-diabetic individuals. Diabetologia 52 (2009), 2345–2349.
57. [57] Zaletel, J., Barlovic, D.P., Prezelj, J., Adiponectin-leptin ratio: a useful estimate of insulin resistance in patients with Type 2 diabetes. J Endocrinol Invest 33 (2010), 514–518.
58. [58] Satoh, N., Naruse, M., Usui, T., Tagami, T., Suganami, T., Yamada, K., et al. Leptin-to-adiponectin ratio as a potential atherogenic index in obese type 2 diabetic patients. Diabetes Care 27 (2004), 2488–2490.
59. [59] Norata, G.D., Raselli, S., Grigore, L., Garlaschelli, K., Dozio, E., Magni, P., et al. Leptin:adiponectin ratio is an independent predictor of intima media thickness of the common carotid artery. Stroke 38 (2007), 2844–2846.
60. [60] Kappelle, P.J., Dullaart, R.P., van Beek, A.P., Hillege, H.L., Wolffenbuttel, B.H., The plasma leptin/adiponectin ratio predicts first cardiovascular event in men: a prospective nested case-control study. Eur J Intern Med 23 (2012), 755–759.
61. [61] Na, L.X., Zhang, Y.L., Li, Y., Liu, L.Y., Li, R., Kong, T., et al. Curcumin improves insulin resistance in skeletal muscle of rats. Nutr Metab Cardiovasc Dis 21 (2011), 526–533.
62. [62] Na, L.X., Li, Y., Pan, H.Z., Zhou, X.L., Sun, D.J., Meng, M., et al. Curcuminoids exert glucose-lowering effect in type 2 diabetes by decreasing serum free fatty acids: a double-blind, placebo-controlled trial. Mol Nutr Food Res 57 (2013), 1569–1577.
63. [63] Tang, Y., Zheng, S., Chen, A., Curcumin eliminates leptin's effects on hepatic stellate cell activation via interrupting leptin signaling. Endocrinology 150 (2009), 3011–3020.
64. [64] Esfahani, M., Movahedian, A., Baranchi, M., Goodarzi, M.T., Adiponectin: an adipokine with protective features against metabolic syndrome. Iran J Basic Med Sci 18 (2015), 430–442.
65. [65] Aggarwal, B.B., Sung, B., Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol Sci 30 (2009), 85–94.